DDRE-17. INITIAL CLINICAL EXPERIENCE USING OSIMERTINIB IN PATIENTS WITH RECURRENT MALIGNANT GLIOMAS WITH EGFR ALTERATIONS

EGFR alterations are commonly observed in malignant gliomas (MG), especially glioblastomas, making this pathway an appealing therapeutic target. Unlike other EGFR tyrosine kinase inhibitors (TKIs), osimertinib (osi), a third-generation, irreversible EGFR-TKI commonly used to treat EGFR-mutant lung c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Abousaud, Marin, Faroqui, Naqeeb, Hsu, Fang-Chi, Lesser, Glenn, Strowd, Roy, Ramkissoon, Shakti, Kwatra, Madan, Houston, Kristin Strickland, Carter, Annette, DeTroye, Alisha
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Drug Discovery, Drug Resistance
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651426/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.262
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados